Thomas Powles

TL;DR: Long-term follow-up from the JAVELIN Bladder 100 trial continues to show prolonged OS, and standard-of-care role for avelumab as 1L maintenance in patients with advanced UC that has not progressed with 1L platinum-containing chemotherapy is supported.

TL;DR: The present review revisits the current evidence base of targeted therapy in combination with surgery for the various disease stages in renal cell carcinoma and proposes surgical targeted therapy for patients at high risk of recurrence after complete resection.

TL;DR: The SIU (Société Internationale d’Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings and came to conclusions and recommendations according to the evidence published.

TL;DR: It is indicated that neoadjuvant therapy followed by prostatectomy may improve long‐term outcomes for patients with high‐risk localized disease and this approach provides a paradigm for evaluating the activity and mechanism of action of new agents as correlative studies are facilitated by the availability of tumor tissue before and after therapy.

TL;DR: Although haematological toxicity is a concern, single agent carboplatin treatment for good prognosis metastatic seminoma could be considered a treatment option and is associated with less toxicity than combination regimens currently used.